Aclaris Therapeutics, Inc. (ACRS) Insider Ownership

Historic Insider Ownership Trends

Over the 90-day window ending February 07, 2026, Aclaris Therapeutics's three dominant insider ownership positions are held by TenPercentOwner Braden Michael Leonard (14.25Mn shares), TenPercentOwner Capital Management Iii, Llc Foresite (3.40Mn shares), Ceo Neal Walker (1.54Mn shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares Report Date
Braden Michael Leonard 14,250,000 05 Aug, 2024
Capital Management Iii, Llc Foresite 3,399,034 03 Nov, 2021
Neal Walker Ceo 1,543,886 05 Feb, 2026
Anand Mehra 714,823 09 Jun, 2025
Andrew N Schiff 448,415 09 Jun, 2025
Joseph Monahan Chief Scientific Officer 265,662 04 Mar, 2025
Frank Ruffo Chief Financial Officer 201,883 14 Mar, 2022
James Loerop Chief Business Officer 192,260 05 Feb, 2026
Kevin Balthaser Chief Financial Officer 185,755 05 Feb, 2026
Kamil Ali-Jackson Chief Legal Officer 160,214 05 Jan, 2022
David N. Gordon Chief Medical Officer 147,447 14 Jul, 2021
Christopher P. Molineaux 57,956 09 Jun, 2025
Hugh M. Davis President And Coo 45,425 05 Feb, 2026
Douglas J. Manion Pres And Ceo 41,813 03 Jan, 2024
William D. Humphries 33,525 09 Jun, 2025
Andrew Kenneth William Powell 33,523 04 Jun, 2024
Bryan M. Reasons 28,732 04 Jun, 2024
Maxine Gowen 21,754 09 Jun, 2025
Vincent Milano 17,316 09 Jun, 2025
Gail Cawkwell Chief Medical Officer 9,593 05 Jul, 2023

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
03 Feb, 2026 Neal Walker Common Stock A 63,475 - 1,562,497 D M
03 Feb, 2026 Neal Walker Common Stock D 18,611 $3.47 1,543,886 D F
03 Feb, 2026 James Loerop Common Stock D 5,937 $3.47 192,260 D F
03 Feb, 2026 James Loerop Common Stock A 20,875 - 198,197 D M
03 Feb, 2026 Kevin Balthaser Common Stock D 6,449 $3.47 185,755 D F
03 Feb, 2026 Kevin Balthaser Common Stock A 22,025 - 192,204 D M
03 Feb, 2026 Hugh M. Davis Common Stock A 18,675 - 45,425 D M
01 Feb, 2026 James Loerop Common Stock D 10,686 $3.51 177,322 D F
01 Feb, 2026 James Loerop Common Stock A 14,750 - 188,008 D M
01 Feb, 2026 James Loerop Common Stock A 11,250 - 165,758 D M
01 Feb, 2026 James Loerop Common Stock A 7,500 - 173,258 D M
01 Feb, 2026 Kevin Balthaser Common Stock D 4,984 $3.51 170,179 D F
01 Feb, 2026 Kevin Balthaser Common Stock A 14,750 - 175,163 D M
02 Jan, 2026 Neal Walker Common Stock D 9,952 $2.88 1,499,022 D F
02 Jan, 2026 Neal Walker Common Stock A 29,150 - 1,508,974 D M
02 Jan, 2026 James Loerop Common Stock D 6,171 $2.88 155,041 D F
02 Jan, 2026 James Loerop Common Stock A 18,150 - 161,212 D M
02 Jan, 2026 Kevin Balthaser Common Stock D 4,461 $2.88 160,413 D F
02 Jan, 2026 Kevin Balthaser Common Stock A 13,200 - 164,874 D M
01 Jan, 2026 Kevin Balthaser Common Stock A 7,500 - 153,924 D M